- Senate passes Drug Quality and Security Act
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- ROUNDTABLE: Pharmacy’s future in sync with technology
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
EAST BRUNSWICK, N.J. — Savient said its newest drug is the first and only therapy available to treat chronic gout in adult patients refractory to conventional therapy.
The drug maker announced the U.S. commercial launch of Krystexxa (pegloticase).
"Since receiving FDA approval for Krystexxa, we have focused on preparing for a successful U.S. launch," said John Johnson, Savient CEO. "Our sales force has completed very thorough and extensive training. We are excited to deploy this highly talented and biologics experienced team into their territories. There has never been a more exciting time in the history of Savient, nor for the chronic gout patients, who have waited so long for a therapy that has the potential to change the course of their lives."